Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Ocugen Shares Positive OCU410 Trial Results for GA
Ocugen has released encouraging preliminary findings from the Phase 1 portion of its Phase 1/2 OCU410 ArMaDa clinical trial, focused on treating geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The results demonstrate the potential of OCU410 as…
Strategies on How Reduce Eye Pressure Instantly
What Is Intraocular Pressure? Eye pressure, also known as intraocular pressure (IOP), is a critical factor in maintaining the health of your eyes. Elevated eye pressure can lead to various eye conditions, including glaucoma, which can result in permanent vision…
FDA Awards Designations to Gildeuretinol for Stargardt
Key Takeaways • Gildeuretinol (ALK-001) has received Rare Pediatric Disease and Fast Track designations, alongside prior Breakthrough Therapy and Orphan Drug statuses, emphasizing its potential to transform treatment for Stargardt disease. • Data from the TEASE-1…
Ray Tracing Optimization – Myopic LASIK & AI
Laser-assisted in situ keratomileusis (LASIK) has become one of the most effective and safe methods for correcting refractive error with laser corneal intervention, as evidenced by the long and large number of publications in the peer-reviewed literature. In recent years,…
SERI and ZEISS Partner to Improve Vision Care
The Singapore Eye Research Institute (SERI) and Carl Zeiss Meditec have launched a groundbreaking collaboration aimed at advancing cataract and refractive surgery outcomes. The initiative, called Ophthalmic Tech Innovation by ZEISS and SERI (OPTIZS), involves a combined investment of nearly…
Alcon’s IOL Faces Probe by CDSCO
The Central Drugs Standard Control Organisation (CDSCO) has formed a committee to investigate allegations of quality issues with an intraocular lens (IOL) supplied by Alcon. The Swiss-American company specializes in eye care products, including lenses for cataract surgery. Specifics of…
OBN Spotlight TV: Interview with Hillary A. Golden
In late October, Medicare introduced proposed Local Coverage Determinations (LCDs) that aimed to impose restrictions on Minimally Invasive Glaucoma Surgery (MIGS) procedures. These LCDs were met with significant concern and opposition from medical professionals, patient advocacy groups, and the ophthalmology…
Innovations in Dry Eye Testing: New Diagnostic Tools
Dry eye disease (DED), also known as keratoconjunctivitis sicca, is one of the most common ophthalmic conditions, affecting hundreds of millions of people worldwide. Recent technological advances and research targeting DED have led to the emergence of new definitions and…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…
MediPrint Announces Positive Results for Glaucoma Lens
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…